Chronic Telogen Effluvium: When Shedding Won't Stop

What Is Chronic Telogen Effluvium?

Chronic telogen effluvium (CTE) is the persistence of abnormally elevated diffuse scalp hair shedding beyond 6 months. It is distinguished from acute telogen effluvium (TE) — which typically peaks and resolves within 3–6 months — by its prolonged, often fluctuating course that can span years.

CTE is not rare. It is one of the most common presentations a dermatologist sees in women of working age, and one of the most emotionally distressing hair conditions because its indefinite timeline creates ongoing uncertainty. Patients often arrive after a long odyssey of inadequate explanations, dismissals, or short-term treatments that failed to address the root cause.

The defining clinical characteristics of CTE are:

• Diffuse shedding — involving the entire scalp, without focal bald patches
• Duration of 6 months or longer, with or without an identifiable initial trigger
• No visible frontal scalp hair loss at Sinclair stage 1 — the hairline and frontal density are preserved
• No follicular miniaturisation on scalp biopsy — distinguishing CTE from female-pattern hair loss
• A fluctuating course — shedding waxes and wanes, making patients doubt whether treatment is working

Who Gets Chronic Telogen Effluvium?

CTE predominantly affects women aged 30–60, with peak incidence in the fourth to fifth decade. The reasons for this female predominance are likely multi-factorial:

• Women in this age group experience more fluctuations in iron stores (through menstruation)
• Thyroid disorders are more prevalent in women
• The hormonal landscape of perimenopause creates vulnerability
• Women are more likely to seek medical care for hair loss

CTE is not exclusively a women's condition, but male CTE is less frequently reported in the literature.

How CTE Differs from Acute Telogen Effluvium

Causes of Chronic Telogen Effluvium

CTE may be primary (idiopathic) — where no systemic cause is found despite thorough investigation — or secondary to an identifiable underlying condition. Secondary causes are important to seek because correcting them is often the most effective treatment.

Iron deficiency

Iron deficiency is one of the most common secondary causes of CTE, particularly in premenopausal women with heavy periods. Critically, anemia is not required — the hair follicle is sensitive to low iron stores at the cellular level before hemoglobin drops below normal range. A serum ferritin below 20 ng/mL is strongly associated with TE; many dermatologists use a threshold of 40 ng/mL as the target for repletion in hair-loss patients.

Thyroid dysfunction

Both hypothyroidism and hyperthyroidism cause diffuse hair shedding. Thyroid-related TE may be the presenting complaint before other symptoms of thyroid disease are apparent, making TSH measurement essential in every CTE workup.

Female-pattern hair loss (androgenetic alopecia)

CTE and female-pattern hair loss (FPHL) frequently coexist. CTE can unmask underlying FPHL that was previously subclinical — the dramatic acute shedding episode creates a threshold of visible thinning that reveals pre-existing progressive follicle miniaturisation. In these patients, treating the TE alone will not restore full density; the androgenetic component requires separate management.

Nutritional deficiency

Protein deficiency, zinc deficiency, and vitamin D deficiency can all perpetuate a chronic shedding state. Protein is the structural building block of the hair shaft; inadequate intake (below approximately 40–60 g per day) prolongs the follicle's telogen phase.

Medications

Ongoing use of a TE-triggering medication — beta-blockers, anticoagulants, retinoids, or certain antidepressants — can maintain CTE for as long as the drug is taken. Review the medication list systematically.

Hormonal changes of perimenopause

The declining estrogen levels of perimenopause reduce hair follicle longevity and may trigger or perpetuate CTE. This is a physiological change rather than a treatable deficiency in most women, though it can overlap with FPHL onset.

Autoimmune and systemic conditions

Systemic lupus erythematosus (SLE), dermatomyositis, and other autoimmune conditions can cause chronic diffuse TE as a manifestation of underlying systemic inflammation.

Idiopathic CTE

After a thorough investigation, a proportion of patients with CTE have no identifiable systemic cause. This primary or idiopathic CTE tends to follow a benign long-term course — shedding fluctuates but does not progress to significant permanent hair loss.

Diagnosis

CTE diagnosis is a process of exclusion combined with positive identification of the pattern.

Clinical criteria for CTE diagnosis

Three criteria must all be present:

1. A history of more than 6 months of increased telogen hair shedding
2. No visible mid-frontal scalp hair loss (Sinclair Stage 1)
3. No hair follicle miniaturisation on scalp biopsy

Examination findings

• Positive or borderline hair pull test (>3 hairs extracted from a grip of 40–60 hairs)
• Diffuse scalp thinning without patterned distribution
• Short regrowing hairs at the hairline during recovery phases

Laboratory investigations

Every patient with suspected CTE should have:

Scalp biopsy

Biopsy is recommended when the diagnosis is uncertain or when CTE needs to be distinguished from androgenetic alopecia or alopecia areata. In CTE, histology shows an elevated ratio of telogen to anagen follicles (>25% telogen), with no follicular miniaturisation and no significant perifollicular inflammation.

Trichoscopy

Video dermatoscopy (trichoscopy) can reveal short regrowing hairs (confirming active regrowth cycle) and helps exclude dermatoscopic signs of other alopecias.

Treatment of Chronic Telogen Effluvium

1. Correct the underlying cause

This remains the cornerstone. Iron repletion in iron-deficient patients, thyroid hormone management, elimination of the offending medication, and nutritional optimization are the highest-yield interventions.

Iron supplementation protocol: Ferrous sulfate 300 mg three to four times daily with food for 3–6 months. Recheck serum ferritin at 3 months; target >40 ng/mL. Vitamin C alongside iron supplementation enhances absorption.

2. Topical minoxidil

Topical minoxidil (2% twice daily or 5% once daily) is the most widely used pharmacological adjunct in CTE. It prolongs the anagen phase and increases follicular blood supply. Results in CTE are variable and often modest compared to its benefit in androgenetic alopecia. A meaningful trial requires at least 6 months.

Patients should be counselled that minoxidil typically causes a brief initial increase in shedding (immediate telogen release — hairs in late telogen are ejected as new anagen growth begins). This is expected and not a reason to discontinue.

3. Oral low-dose minoxidil

The most robust CTE pharmacological data involves oral minoxidil at low doses. A retrospective study of 36 women (mean age 46.9 years, mean disease duration 6.55 years) treated with oral minoxidil ranging from 0.25 mg to 2.5 mg once daily demonstrated:

• Significant reduction in shedding scores from baseline to 6 months (p<0.001)
• Further significant improvement from baseline to 12 months (p<0.001)
• 31 of 36 patients improved at 6 months; 33 of 36 by 12 months
• Main side effect: facial hypertrichosis (unwanted facial hair) in 13 of 36 patients
• Minimal haemodynamic effects (mean blood pressure change was clinically insignificant)

Oral minoxidil for CTE should be initiated and monitored by a dermatologist. It is not suitable for patients with cardiovascular disease.

4. Nutritional support

Ensure adequate dietary protein (a minimum of 40–60 g per day — two palm-sized portions of protein per day roughly meets this). Mediterranean-style dietary patterns may support overall hair health. Avoid crash diets or very low-calorie restriction.

5. Psychological support

The chronic nature of CTE is psychologically wearing. The fluctuating course — some weeks better, some weeks worse — makes it difficult for patients to trust that treatment is working. A dermatologist should:

• Explain the natural history clearly, including that the absence of total baldness is a feature of CTE
• Set realistic expectations about timelines (improvement over months, not weeks)
• Consider referral for psychological support if hair loss anxiety is significantly impacting quality of life

Prognosis

CTE does not cause permanent baldness. Follicles in CTE retain their structural integrity and capacity for regrowth. The outlook depends on whether an underlying cause can be identified:

• Identifiable secondary cause corrected: shedding typically improves significantly within 3–6 months of addressing the cause, with continued improvement over 12–18 months
• Idiopathic CTE: tends to follow a prolonged but ultimately self-limiting course; many patients report natural resolution over several years, though the timeline is unpredictable
• CTE with concurrent FPHL: shedding from the TE component may resolve, but underlying androgenetic hair thinning will continue and requires separate treatment (topical or oral minoxidil, antiandrogens)